Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Recruiting in Palo Alto (17 mi)

+144 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Dermavant Sciences, Inc.

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.

Research Team

Diana Villalobos

Principal Investigator

Dermavant Sciences, Inc.

Eligibility Criteria

Inclusion Criteria

You are male or female and you have clinical diagnosis of Alzheimer's disease.

You have a score of 3 or higher on a test called vIGA-AD during screening and baseline evaluations.

You have a skin condition with an EASI score of 6 or higher at screening and baseline.

Treatment Details

Interventions

• tapinarof cream, 1% (Topical Agent)
• Vehicle cream (Topical Agent)

Participant Groups

Group I: tapinarof cream Experimental Treatment 1 Intervention

tapinarof cream, 1%, applied topically once daily

Group II: vehicle cream Placebo Group 1 Intervention

vehicle cream, applied topically once daily

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Dermavant Investigative Site Phoenix, AZ

Dermavant Clinical Site Mission Viejo, CA

Dermavant Clinical Site Boca Raton, FL

Dermavant Clinical Site Margate, FL

More Trial Locations

Who Is Running the Clinical Trial?

Dermavant Sciences, Inc.

Lead Sponsor

Trials

9

Patients Recruited

1,800+

Dermavant Sciences GmbH

Lead Sponsor

Trials

13

Patients Recruited

3,100+